Compositions and methods for using purified human rna editing enzymes

3-4. (canceled)

5:

• A method for eradicating or reducing in vivo numbers of cancer stem cells comprising administering to an individual in need thereof an ADAR1 (adenosine deaminase associated with RNA1) inhibiting agent, wherein the ADAR1 inhibiting agent reduces, or significantly reduces, ADAR1 levels in vivo,
• wherein optionally the ADAR1 inhibiting agent reduces, or significantly reduces, ADAR1 Nano-luc reporter activity,
• wherein optionally the ADAR1 inhibiting agent reduces, or significantly reduces, ADAR1 in cell lines and/or in human cancer stem cell assays.

6:

• The method of claim 5, wherein said ADAR1 inhibiting agent comprises a JAK2 inhibitor.

7:

• The method of claim 6, wherein the JAK2 inhibitor comprises fedratinib, or INREBIC™, or ruxolitinib, or JAKAFI™.

8:

• The method of claim 5, wherein said ADAR1 inhibiting agent comprises a STAT3 inhibitor.

9:

• The method of claim 5, wherein the ADAR1 inhibiting agent comprises 8-aza-adenosine, a nucleoside analog or an integrase inhibitor.

10:

• The method of claim 5, wherein the ADAR1 inhibiting agent comprises raltegravir (or ISENTRESS™) or dolutegravir (or TIVICAY™).

11:

• The method of claim 5, wherein the ADAR1 inhibiting agent comprises a lentiviral shRNA ADAR1 knockdown vector.

12:

• The method of claim 5, wherein the ADAR1 inhibiting agent comprises a lentiviral ADAR1 mutant vector.

13:

• The method of claim 5, wherein the ADAR1 inhibiting agent comprises a lentiviral ADAR1 Z alpha domain deleted vector.

14:

• The method of claim 5, wherein ADAR1 inhibiting agent comprises an interferon inhibitory compound.

15:

• The method of claim 5, wherein the ADAR1 inhibiting agent comprises lentiviral ADAR1 or lentiviral ADAR1 shRNA.

16:

• The method of claim 5, wherein the ADAR1 inhibiting agent comprises a recombinant human full length ADAR1.

17:

• The method of claim 6, wherein the ADAR1 inhibiting agent comprises a recombinant human ADAR1 catalytic domain.

18:

• The method of claim 5, wherein the ADAR1 inhibiting agent comprises a recombinant human Z alpha domain deleted ADAR1.

19:

• The method of claim 5, wherein the ADAR1 inhibiting agent comprises a JAK2-expressing vector, optionally a retroviral or a lentiviral JAK2 expression vector, optionally a retroviral or a lentiviral JAK2 overexpression vector.

20:

• The method of claim 5, wherein the ADAR1 inhibiting agent is formulated or manufactured as a parenteral formulation, an aqueous solution, a liposome, an injectable solution, a tablet, a pill, a lozenge, a capsule, a caplet, a spray, a sachet, an inhalant, a powder, a freeze-dried powder, an inhalant, a patch, a gel, a geltab, a nanosuspension, a nanoparticle, a nanoliposome, a microgel, a pellet, a suppository or any combination thereof,
• and optionally the drug delivery device or product of manufacture is or comprises an implant.

21:

• The method of claim 5, wherein the ADAR1 inhibiting agent is are formulated or manufactured together in one parenteral formulation, one aqueous solution, one liposome, one injectable solution, one freeze-dried powder, one feed, one food, one food supplement, one pellet, one lozenge, one liquid, one elixir, one aerosol, one inhalant, one adhesive, one spray, one powder, one freeze-dried powder, one patch, one tablet, one pill, one capsule, one gel, one geltab, one lozenge, one caplet, one nanosuspension, one nanoparticle, one nanoliposome, one microgel or one suppository.

22:

• The method of claim 5, wherein the ADAR1 inhibiting agent is formulated in a unit dosage amount ranging from between 0.1 mg to about 1 gram, and optionally formulated as an immediate release formulation or a controlled release formulation.

23-31. (canceled)